When does OncoTherapy (4564.T) report earnings?

OncoTherapy (4564.T) will announce results on **2026-01-30**. The report should cover clinical updates, R&D spend and cash position, key items that typically move the stock in the JPX pre-market session.

What are the main valuation metrics for 4564.T stock?

Key metrics: **EPS -2.83**, **PE -7.77** (negative), **PB 4.06**, cash per share **¥5.26**, and a strong current ratio **8.63**. These figures show liquidity strength and earnings weakness.

How does Meyka AI view 4564.T stock ahead of earnings?

Meyka AI rates 4564.T **65.52/100 (B, HOLD)**. The model highlights clinical catalysts and a mixed forecast: monthly **¥28.51** and yearly **¥18.22**. Forecasts are projections and not guarantees.

What technical signals should traders watch for 4564.T?

Watch **RSI 68.81** and **CCI 277.90** for short-term overbought risk, MACD histogram **0.40** for momentum, and ATR **¥1.54** for expected daily range. Volume below average can amplify moves.

JP Stocks

4564.T OncoTherapy Science (JPX) pre-market: earnings Jan 30 could shift price

ByDanny Kontos January 27, 2026January 27, 2026

The 4564.T stock opened pre-market at ¥22.00, up 4.76%, as investors position ahead of OncoTherapy Science’s earnings on 30 Jan 2026. Volume is 25,430,900 versus a 50-day average of 53,676,932, showing subdued liquidity but increased interest. Upcoming clinical updates and cash runway will likely drive the report and short-term volatility on the JPX market in Japan.